Pros | ![]() Lower expense ratio. ![]() Beats FD returns for both 3Y & 5Y duration. | ![]() Beats FD returns for both 3Y & 5Y duration. | ||
Cons | ![]() 3Y returns in the bottom 25% of the category. | ![]() 5Y returns in the bottom 25% of the category. ![]() 3Y returns in the bottom 25% of the category. |
INDMoney rank | 5/8 | 8/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 6 Years | 5 Years | ||
Fund Size | 2667 Cr | 815 Cr | ||
Min Investment | SIP ₹99 Lumpsum ₹5000 | SIP ₹100 Lumpsum ₹1000 | ||
Expense Ratio | 0.61% | 1.1% | ||
Exit Load | 1% | 1% | ||
Benchmark Index | BSE Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 34 | 29 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (11.9%) Aurobindo Pharma Ltd (7.12%) Cipla Ltd (6.91%) Divi's Laboratories Ltd (6.6%) Lupin Ltd (6.2%) | Sun Pharmaceuticals Industries Ltd (14.49%) Cipla Ltd (8.9%) Torrent Pharmaceuticals Ltd (7.6%) Abbott India Ltd (6.56%) Apollo Hospitals Enterprise Ltd (5.93%) | ||
No of Sectors | 3 | 2 | ||
Top 3 Sectors | Health (98.7%) Basic Materials (1.3%) Industrial (0%) | Health (99.2%) Basic Materials (0.8%) | ||
Equity % | 99.55% | 98.62% | ||
Debt % | - | - | ||
P/E | 34.28 | 35.29 | ||
P/B | 5.04 | 5.9 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 4.15% | 4.41% | ||
3-Month Return | -2.87% | -2.94% | ||
6-Month Return | -8.33% | -9.28% | ||
1-Year Return | 18.31% | 14.02% | ||
3-Year Return | 18.37% | 18.14% | ||
5-Year Return | 24.64% | 21.11% |
Sharpe | 0.76 | 0.74 | ||
Alpha | -0.36 | -0.56 | ||
Beta | 0.98 | 0.96 | ||
Standard Deviation | 17.14 | 16.88 | ||
Information Ratio | -0.24 | -0.34 |
Description | Mirae Asset Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Vrijesh Kasera | Dhaval Shah |